BioVersys AG (FRA:W33) Stock Based Compensation: €0.71 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:W33 BioVersys AG FRA:W33
16 GF Score
Price €28.60
View Full Analysis

What is BioVersys AG Stock Based Compensation?

BioVersys AG FRA:W33 +1.42% 16 Stock Based Compensation is €0.71 Mil as of Dec. 2025. GuruFocus rates FRA:W33 with a GF Score™ of 16/100.

BioVersys AG's Stock Based Compensation for the six months ended in Dec. 2025 was €0.52 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was €0.71 Mil.

BioVersys AG Stock Based Compensation Related Terms

BioVersys AG Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Stock Based Compensation Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Stock Based Compensation
1.99 0.71

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Stock Based Compensation 1.64 0.30 0.19 0.52
FRA:W33
16GF Score
BioVersys AG FRA:W33
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.71 Mil.

What does a Stock Based Compensation of €0.71 Mil mean?
BioVersys AG (FRA:W33) has a Stock Based Compensation of €0.71 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for BioVersys AG and its competitors.
Is BioVersys AG's Stock Based Compensation too high?
BioVersys AG's current Stock Based Compensation is €0.71 Mil. Overall, BioVersys AG has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Stock Based Compensation compare to VRTX and REGN?
BioVersys AG's Stock Based Compensation of €0.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for BioVersys AG and its competitors. BioVersys AG's current Stock Based Compensation is €0.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (FRA:W33) has a current Stock Based Compensation of €0.71 Mil. The current Stock Based Compensation is €0.71 Mil. BioVersys AG's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For BioVersys AG (FRA:W33), the current Stock Based Compensation is €0.71 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKBIOV:Switzerland
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
16GF Score

Get the complete analysis for FRA:W33

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.60
Price